ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Papadimitrakopoulou on Immunotherapy Combinations in Lung Cancer

Vassiliki A. Papadimitrakopoulou, MD
Published: Tuesday, Mar 28, 2017



Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses trials investigating combinations of immunotherapy regimens in lung cancer.

The combination of chemotherapy and anti–PD-1 appears to be active in all-comers with no prerequisite or high expression of PD-L1, making this indication an interesting proposition for patients who may not be candidates for the standard of care pembrolizumab (Keytruda), explains Papadimitrakopoulou.

In regards to the combination of anti–PD-1 and anti–CTLA-4, the frontline study that included a small number of patients investigated the combination of nivlolumab (Opdivo) and ipilimumab (Yervoy) and suggested high response rates and a long duration of response. However, the data from this study is limited and there needs to be confirmatory trials with larger groups of patients, states Papadimitrakopoulou.
 


Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses trials investigating combinations of immunotherapy regimens in lung cancer.

The combination of chemotherapy and anti–PD-1 appears to be active in all-comers with no prerequisite or high expression of PD-L1, making this indication an interesting proposition for patients who may not be candidates for the standard of care pembrolizumab (Keytruda), explains Papadimitrakopoulou.

In regards to the combination of anti–PD-1 and anti–CTLA-4, the frontline study that included a small number of patients investigated the combination of nivlolumab (Opdivo) and ipilimumab (Yervoy) and suggested high response rates and a long duration of response. However, the data from this study is limited and there needs to be confirmatory trials with larger groups of patients, states Papadimitrakopoulou.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x